New frontiers innlipid managment: The role of inclisiran in cardiovascular risk reduction

Abstract

-ASCVD Pathogenesis: Atherosclerotic Cardiovascular Disease remains the leading global cause of death, progressing from initial lipid retention and inflammation to the development of vulnerable plaques susceptible to life-threatening rupture. -Diagnostic Evolution: Beyond basic lipid profiles, modern 2026 clinical assessments now integrate high-sensitivity C-reactive protein (hsCRP), calcium scoring, and ankle-brachial index (ABI) to provide a more comprehensive view of vascular health. -Addressing the Adherence Gap: While traditional statins and ezetimibe are effective, the chronic "adherence gap" of daily oral medications has historically limited the success of long-term risk reduction. -The siRNA Frontier: Inclisiran has revolutionized therapy by utilizing a GalNAc delivery system to enter hepatocytes and leverage the RNA-induced silencing complex (RISC) to stop PCSK9 production at the genetic level. -Clinical Validation: Extensively validated by the ORION trial program, this siRNA therapy provides stable and durable LDL-C reduction through a convenient biannual dosing schedule administered by healthcare providers